Orbus Therapeutics racks up $32.5 mln Series A

By Iris Dorbian — 6 months ago

Orbus Therapeutics Inc, a biopharmaceutical company focused on treating rare diseases, has closed $32.5 million in Series A funding. Longitude Capital, H.I.G. BioVentures and Adams Street Partners led the round. Also, the company has named Dr. Ernest Mario, an investor in this current round, as chairman of board.

Continue

Calhoun Vision nets $69 mln

By Iris Dorbian — 8 months ago

Calhoun Vision Inc, a provider of adjustable intraocular lens technology, has raised $69 million in funding. Longitude Capital led the round with participation from H.I.G. BioVentures, Balance Point Capital Partners and RA Capital Management.

Continue

NeuWave Medical scores $25 mln Series C

By Iris Dorbian — 9 months ago

Madison, Wisconsin-based medical device company NeuWave Medical Inc has closed $25 million in Series C financing. Versant Ventures led the round with participation from other investors that included H.I.G. BioVentures and Venture Investors. In conjunction with the funding, NeuWave has added Kirk Nielsen, managing director at Versant Ventures, to its board of directors.

Continue

NEA leads $38.9 mln Series B funding in Intact Vascular

By Chris Witkowsky — 9 months ago

New Enterprise Associates led a $38.9 million Series B funding round in Intact Vascular, Inc., which develops medical devices for minimally invasive vascular procedures. Other participants in the funding included Quaker Partners, H.I.G. BioVentures and other existing investors. NEA Partner Justin Klein joined Intact Vascular’s board. Press Release Intact Vascular, Inc., a developer of medical […]

Continue

H.I.G. BioVentures leads Series C round for ForSight VISION5

By Iris Dorbian — 2 years ago

ForSight VISION5 has closed $15 million in Series C financing. H.I.G. BioVentures led the round with participation from previous backers Morgenthaler Ventures, Versant Ventures, Technology Partners and Delphi Ventures. Concurrent with the funding, Aaron Davidson of H.I.G. BioVentures has been added to ForSight VISION5’s board of directors. Based in Menlo Park, Calif., ForSight VISION5 focuses on developing products that replace eye drops.

Continue

Iconic Therapeutics snags $20 mln

By Iris Dorbian — 2 years ago

Iconic Therapeutics said Wednesday that it has closed $20 million in Series B-1 financing. The investors were MPM Capital, Lundbeckfond Ventures and H.I.G. BioVentures. In conjunction with the funding, Iconic has named MPM partner Dr. William Greene as CEO. Also, MPM’s Todd Foley, H.I.G’s Dr. Bruce Robertson and Dr. Johan Kordel of Lundbeckfond Ventures have been added to Iconic’s board of directors. Based in South San Francisco and Atlanta, Iconic is a biotech firm focused on serious eye disorders.

Continue